Idelalisib Receives FDA Approval for CLL, Accelerated Approval for Follicular Lymphoma and SLL Patients

Richard Furman, MD
Richard Furman, MD

Recently the FDA approved Zydelig (idelalisib) for the treatment of patients who experienced a relapse in their chronic lymphocytic leukemia (CLL). For patients with CLL, the approval of idelalisib is intended for use in combination with Rituxan (rituximab). Additionally, the FDA granted accelerated approval for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL).

The effectiveness of idelalisib for these blood cancers was determined in several clinical trials. For CLL a trial with 220 patients established the safety and effectiveness of the drug by comparing idelalisib and rituximab to the combination of a placebo and rituximab. At the first analysis interval the study was stopped due to the efficacy displayed by the idelalisib and rituximab combination when compared to rituximab by itself. The progression free survival rates of patients who received idelalisib and rituximab was 10.7 months compared to the 5.5 months for patients who received the placebo and rituximab.

Further trials established the safety and effectiveness of idelalisib in the treatment of relapsed FL and SLL patients. 123 participants were evaluated for their overall response rate to idelalisib, with 54% of relapsed FL patients, and 58% of SLL patients achieving an objective response rate, which measures the partial or complete disappearance of cancer after treatment.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s